

MAHARASHTRA MEDICAL GOODS PROCUREMENT AUTHORITY

Expression of Interest (EOI) for Market Assessment of Original Manufacturers and Authorized Importers for Supply of Liquid Orals (Year 2026-27)

**EOI reference No: E-291/MMGPA/ EOI for Liquid Orals
(2026-27)**

1st Floor, Aarogya Bhawan St. George's Hospital Compound,
Near C.S.M.T. Railway Station, Mumbai - 400 001.
Maharashtra

Website: <http://mahatenders.gov.in>

Email: maha.mmghpa2023@gmail.com Phone : 022-22717527

Table of Contents

Table of Contents.....	2
Disclaimer	4
Abbreviations and Glossary	6
Notice and Schedule Inviting Expression of Interest (EOI)	7
EOI Notice	7
Section 1: Introduction	8
Section 2: General Definitions	9
Section 3: General Terms and Conditions	10
3.1 Responsibility of verification of contents of EOI	10
3.2 Acknowledgement of the Responder	10
3.3 Period of Validity of EOI	10
3.4 Nature of the Expression of Interest.....	10
3.5 Responsibility of EOI Respondents	11
3.6 Submission of EOI Responses	11
3.7 Clarifications and Amendments.....	11
3.8 Conflict of Interest	12
3.9 Fraudulent and Corrupt Practices.....	12
3.10 Confidentiality	12
3.11 Governing Law	12
3.12 Respondents Information	12
3.13 Manufacturing/Importing and Product Permissions	14
3.14 Delivery Capability	14
3.15 Respondent Classification.....	15
3.16 Eligibility Criteria	15
Appendix A: Schedule of Requirements	23
Appendix B: Checklist	37
Annexure 1: Technical Specifications and Compliance	40
Annexure-2: Undertaking by EoI Respondent	42
Annexure-3: Proforma for Production and Sale Statement	44
Annexure 4: Details of Manufacturing Unit.....	45
Annexure-4 (A): Proof of Distribution Network.....	48
Annexure-5: Details of Items Quoted with Drug Code	49
Annexure 6: Annual Turnover Statement for Three Years	50
Annexure-7: Format for Power of Attorney for signing of EOI.....	52

Annexure-8: Undertaking for Non-blacklisting	54
Annexure- 9: Litigation Affidavit.....	55
Annexure-10: Litigation Affidavit.....	56
Annexure 11: Delivery and Supply Capability.....	57
Annexure 11 (a) : Delivery Acceptance Certificate.....	58
Annexure 12: Respondent Classification Details	59

Disclaimer

This Expression of Interest (EOI) Document is not an agreement and is neither an offer nor invitation by the MMGPA to the prospective EOI Responders or any other person. The purpose of this Expression of Interest (EOI) Document is to invite interested and eligible entities to provide information relating to their regulatory status, manufacturing capability, quality systems, market presence, and related parameters, solely to enable MMGPA to undertake a market assessment and planning exercise in connection with any potential future procurement of Liquid Orals.

This Expression of Interest (EOI) Document contains information, statements, and indicative details prepared by MMGPA solely for the purpose of facilitating a broad market assessment and planning exercise in relation to the potential future procurement of Liquid Orals. Such information and statements are based on assumptions, preliminary assessments, and internal considerations and are not intended to be exhaustive or definitive. This EOI Document may not address the specific circumstances, operational capacities, or regulatory positions of every interested entity, and MMGPA, its employees, or advisors do not undertake to consider the individual requirements of each person or entity reviewing or responding to this document. The information provided herein may be subject to change and may not be complete, accurate, or current in all respects. Each EOI Respondent is therefore advised to conduct its own assessment, verification, and analysis of the information contained in this EOI Document and to seek independent professional or technical advice as it considers appropriate.

Information provided in this Expression of Interest (EOI) Document to the EOI Responder(s) is on a wide range of matters, some of which may depend upon interpretation of law. The information given is not intended to be an exhaustive account of statutory requirements and should not be regarded as a complete or authoritative statement of law. The MMGPA accepts no responsibility for the accuracy or otherwise for any interpretation or opinion on law expressed herein.

The MMGPA, its employees and advisors make no representation or warranty and shall have no liability to any person, including any EOI Responder(s) under any law, statute, rules or regulations or tort, principles of restitution or unjust enrichment or otherwise for any loss, damages, cost or expense which may arise from or be incurred or suffered on account of anything contained in this Expression of Interest (EOI) Document or otherwise, including the accuracy, adequacy, correctness, completeness or reliability of the Expression of Interest (EOI) Document and any assessment, assumption, statement or information contained therein or deemed to form part of this Expression of Interest (EOI) Document or arising in any way for participation in this Expression of Interest (EOI) Document.

The MMGPA may, in its absolute discretion but without being under any obligation to do so, update, amend or supplement the information, assessment or assumptions contained in this Expression of Interest (EOI) Document.

The EOI Responder(s) shall bear all its costs associated with or relating to the preparation and submission of its EOI Response including but not limited to preparation, copying, postage, delivery fees, expenses associated with any demonstrations or presentations which may be required by the MMGPA, or any other costs incurred in connection with or relating to its EOI Response. All such costs and expenses will remain with the EOI Responder(s) and the MMGPA shall not be liable in any manner whatsoever for the same or for any other costs or other expenses incurred by a EOI Responder(s) in preparation or submission of the EOI Response, regardless of the conduct or outcome of the responding process. The MMGPA also accepts no liability of any nature whether resulting from negligence or otherwise howsoever caused arising from reliance of any EOI Responder(s) upon the statements contained in this Expression of Interest (EOI) Document.

MMGPA shall not be responsible or liable for any costs, expenses, or losses incurred by EOI Respondents in connection with preparation or submission of EOI Responses, regardless of the outcome of the EOI process. Participation in this Expression of Interest (EOI) shall not confer any right or entitlement on the EOI Respondents to participate in any subsequent procurement process.

MMGPA reserves the right to independently determine the eligibility criteria, qualification requirements, and procurement strategy in any future tender process, without any reference to or obligation arising from this EOI.

Abbreviations and Glossary

Abbreviations	Description
BET	Bacterial Endotoxin Test
BIS	Bureau of Indian Standards
BP	British Pharmacopeia
CA	Chartered Accountant
CLA	Central Level Authority
COPP	Certificate of Pharmaceutical Products
CT	Clinical Trials
DCGI	Drug Controller General of India
DMER	Directorate of Medical Education & Research
DPCO	Drug Price Control Order
DPIIT	Department for Promotion of Industry and Internal Trade
ESIC	Employees State Insurance Corporation
FDA	Food and Drug Administration
FEMA	Foreign Exchange Management Act 1999
GMP	Good Manufacturing Practices
G.R.	Government Resolution
GST	Goods and Services Tax
GS1	Global Standards1
HBPCL	Haffkine Bio-Pharmaceutical Corporation Limited
IEC	Import Export Code
IP	Indian Pharmacopeia
ISI	Indian Standards Institute
I.V.	Intra Venous
LLP	Limited Liability Partnership
MCGM	Municipal Corporation of Greater Mumbai
MDR	Medical Device Rules
MMGPA	Maharashtra Medical Goods Procurement Authority
MRP	Maximum Retail Price
MSC	Market Standing Certificate
MSEs	Micro and Small Enterprises
NABL	National Accreditation Board for Laboratories
NSQ	Not of Standard Quality
NPPA	National Pharmaceutical Pricing Authority
OEM	Original Equipment Manufacturer
PAN	Permanent Account Number
PoA	Power of Attorney
PVC	Poly Vinyl Chloride
PVdC	Poly Vinylidene Chloride
SLA	State Level Authority
SSI	Small Scale Industries
UDIN	Unique Document Identification Number
USP	United States Pharmacopeia
WHO	World Health Organization

Notice and Schedule Inviting Expression of Interest (EOI)

EOI Notice

The Maharashtra Medical Goods Procurement Authority (MMGPA) invites Expressions of Interest (EOI) from eligible Original Manufacturers (OEMs) and their Authorized Importers for assessing market capability, regulatory compliance, manufacturing capacity, and delivery capability for supply of Liquid Orals to public health institutions in the State of Maharashtra.

This EOI is a non-binding, pre-procurement exercise and does not constitute a tender or offer of contract. No price submissions, financial offers, or securities are required at this stage.

The objective of this EOI is to assess the number of eligible and capable OEMs and Authorized Importers available for the listed Liquid Orals and their readiness to participate in future procurement processes.

The information collected through this EOI will be used for planning future procurement strategies. MMGPA reserves the right to initiate or not initiate any subsequent tender or rate contract process without any obligation to the EOI respondents.

Only Original Manufacturers or their Authorized Importers are eligible to participate. Traders, distributors, and other intermediaries are not permitted.

Interested entities meeting the eligibility conditions are invited to submit their EOI responses within the timelines specified in this document.

EOI responses must be submitted within fifteen (15) days from the date of publication of this EOI. Late submissions shall not be accepted.

All response-related activities, including downloading of documents and submission of responses, shall be governed by the schedule indicated below.

EOI Response Schedule

No.	Activity	Date & Time
1	Publication of Notice Inviting Expression of Interest (EOI)	From 27.05.2026 , 11.00 AM
2	Last date and time for submission of EOI Responses	dt.10.06.2026 at 3:00 PM
3	Opening of EOI Responses (Technical & capability only, No price information shall be submitted)	dt. 11.06.2026 at 3:00 PM
4	EoI Clarification Meeting	From 03.06.2026 , 02:00 PM
5	Address for communication	Meeting Hall, 1st Floor, Aarogya Bhawan, St. Georges Hospital Compound, Near CSMT Railway Station, Mumbai- 400 001

Sd/-

CHIEF EXECUTIVE OFFICER,
MAHARASHTRA MEDICAL GOODS
PROCUREMENT AUTHORITY
MUMBAI

Section 1: Introduction

Maharashtra Medical Goods Procurement Authority (MMGPA), Mumbai has been formed as per the Maharashtra Medical Goods Procurement Authority Act 2023 (Mah. Act No. XIII of 2023) (“Act”).

MMGPA works as a single point procurement authority of certain medical goods and execution of turnkey projects with highest standards of transparency, fairness, equity and for timely supply at optimum and uniform rates and of desired quality and quantity for the Public Health Department, Medical Education & Drug Department of Government of Maharashtra and other departments as mentioned in the said Act.

To meet the objective of the Act, MMGPA in exercise of its powers under section 36 of the Act issued the regulations named, Maharashtra Medical Goods Procurement Authority Regulations, 2025 as amended from time to time.

- 1.1 All related activities (process) like EOI downloading and response submission will be governed by the EOI Schedule.
- 1.2 All activities of this EOI are carried out online on website <https://mahatenders.gov.in>. The EOI is uploaded on Government of Maharashtra, (GoM) e-tendering website <https://mahatenders.gov.in> and has to be downloaded as well as filled up and submitted online only.
- 1.3 No commitment is made by MMGPA regarding procurement of any quantity pursuant to this EOI, and the Authority reserves the right to modify, expand, curtail, or altogether omit any items or quantities in any subsequent procurement process, if undertaken
- 1.4 EOI process related Queries can be sent on email – eproc.support@maharashtra.gov.in /Help: The 24 x 7 Toll Free Telephonic Help Desk Number 1800-3070-2232. / Mobile: +91-7878107985, +91-7878107986, +91-7878007972 and +91-7878007973.

Sd/-
CHIEF EXECUTIVE OFFICER,
MAHARASHTRA MEDICAL GOODS
PROCUREMENT AUTHORITY
MUMBAI

Section 2: General Definitions

For the purposes of this Expression of Interest (EOI) Document, and unless the context otherwise requires, the following terms shall have the meanings assigned to them below:

- 2.1 **“Applicable Laws”** Means all laws, statutes, rules, regulations, notifications, guidelines, and policies in force in India as issued by the Government of India or the Government of Maharashtra, including but not limited to the Drugs and Cosmetics Act, 1940 and Rules thereunder, Medical Device Rules, 2017, New Drugs and Clinical Trials Rules, 2019, NPPA/DPCO provisions, and other applicable regulatory requirements, as amended from time to time.
- 2.2 **“Authority” or “MMGPA”** Means the Maharashtra Medical Goods Procurement Authority, established under the Maharashtra Medical Goods Procurement Authority Act, 2023.
- 2.3 **“Expression of Interest” or “EOI”** Means this non-binding, pre-procurement process initiated by MMGPA to solicit information regarding market capability, regulatory compliance, manufacturing capacity, and quality systems from eligible entities.
- 2.4 **“EOI Document”** Means this document, including all sections, appendices, annexures (if any), and amendments issued by MMGPA in connection with the Expression of Interest.
- 2.5 **“EOI Response”** Means the information and declarations submitted by an EOI Respondent in response to this EOI Document, limited to technical, regulatory, manufacturing, and capability-related information.
- 2.6 **“EOI Respondent”** Means any manufacturer or importer who submits an EOI Response pursuant to this EOI Document.
- 2.7 **“Conflict of Interest”** Means any situation in which an EOI Respondent has interests that could improperly influence its participation in the EOI process, including but not limited to relationships that compromise fairness, transparency, or objectivity.
- 2.8 **“Fraudulent or Corrupt Practices”** Means misrepresentation, concealment of facts, submission of false or forged documents, or any attempt to influence the EOI process improperly.
- 2.9 **“Government”** Means the Government of India or the Government of Maharashtra, as applicable.

Interpretation Words and expressions used but not defined in this EOI Document shall have the meanings assigned to them under Applicable Laws.

Note: The words and expressions used in this EOI, but not defined, shall have the same meaning as respectively assigned to them under the prevailing Applicable Laws.

Section 3: General Terms and Conditions

This section deals with the general conditions of the EOI and contains the following terms & conditions governing the EOI.

3.1 Responsibility of verification of contents of EOI

- 3.1.1 It shall be the responsibility of the EOI Responders to read/examine all instructions, forms, terms, conditions, specifications, schedules, appendix, annexures and other provisions contained in the Expression of Interest (EOI) Document, including any addendum or corrigendum issued thereunder prior to submission of the response.
- 3.1.2 Responders shall ensure that all required documents as specified in **Appendix A (Checklist)** are duly uploaded.

3.2 Acknowledgement of the Responder

- 3.2.1 It shall be deemed that by submitting the EOI, the Responder has:
- i. examined the EOI Document and understood its contents.
 - ii. received all relevant information available from MMGPA
 - iii. acknowledged and agreed that inadequacy, lack of completeness or incorrectness of information provided in the Expression of Interest (EOI) Documents shall not be a basis for any claim for compensation, damages or extension of time.
 - iv. acknowledged that it does not have a Conflict of Interest as per Clause 3.9 and
 - v. agreed to be bound by the provisions and undertakings provided by it under and in terms hereof.

MMGPA shall not be liable for any omission, mistake or error in respect of any of the above or on account of any matter or thing arising out of or concerning or relating to the EOI or its Responding process, including any error or mistake therein or in any information or data given by MMGPA.

3.3 Period of Validity of EOI

- 3.3.1 The EOI Response submitted pursuant to this document shall remain valid for the purpose of this EOI process only until completion of the EOI exercise or initiation of any subsequent procurement process, whichever is earlier.

3.4 Nature of the Expression of Interest

- 3.4.1 The information received pursuant to this EOI shall be used by MMGPA only for:
- a) market assessment and planning,
 - b) identification of technically and regulatorily suitable entities, and
 - c) formulation of future procurement strategies, if any.
- 3.4.2 This Expression of Interest (EOI) is a non-binding, pre-procurement exercise issued solely for the purpose of assessing market capability, regulatory compliance, manufacturing capacity, and quality systems of eligible entities.
- 3.4.3 Submission of an EOI Response does not constitute a bid, tender, or offer, and does not create any contractual, financial, or legal obligation on either MMGPA or the EOI Respondent.

- 3.4.4 MMGPA reserves the right to initiate or not initiate any subsequent procurement process, including a tender or RFP, without assigning any reason.
- 3.4.5 The EOI is intended to assess the number of eligible and capable Original Manufacturers and Authorized Importers available for each essential medicine/item and their readiness to participate in future procurement processes.

3.5 Responsibility of EOI Respondents

- 3.5.1 Each EOI Respondent shall:
- a) carefully examine the EOI Document and all instructions therein;
 - b) ensure that all information and documents submitted are true, accurate, and complete to the best of its knowledge;
 - c) satisfy itself regarding the scope, intent, and implications of the EOI.
 - d) Any misrepresentation, concealment, or submission of false information may result in rejection of the EOI Response.
- 3.5.2 Respondents shall provide accurate information regarding:
- (a) availability of medicines/item(s) against the provided list,
 - (b) manufacturing/import capacity,
 - (c) indicative delivery timelines.

3.6 Submission of EOI Responses

- 3.6.1 EOI Responses must be submitted within fifteen (15) days from the date of publication of the EOI. Late submissions shall not be accepted.
- 3.6.2 The EOI Response shall be limited to technical, regulatory, manufacturing, and capability-related information only.
- 3.6.3 No price bids, financial offers, bid securities, earnest money deposits, or payments of any kind are required or permitted at the EOI stage.

3.7 Clarifications and Amendments

- 3.7.1 EOI Respondents may seek clarification, within the timelines specified in the EOI Schedule.
- 3.7.2 MMGPA may, at its discretion:
- a) **issue clarifications,**
 - b) **amend the EOI Document, or**
 - c) **modify the EOI Schedule.**
- 3.7.3 All such clarifications or amendments shall form an integral part of the EOI Document.

3.8 Conflict of Interest

- 3.8.1 EOI Respondents shall disclose any actual or potential conflict of interest that may affect their participation in the EOI process.
- 3.8.2 MMGPA reserves the right to reject an EOI Response where a conflict of interest is found to compromise fairness, transparency, or objectivity.

3.9 Fraudulent and Corrupt Practices

- 3.9.1 EOI Respondents shall observe the highest ethical standards during the EOI process.
- 3.9.2 Any attempt to:
- a) misrepresent facts,
 - b) submit forged or misleading documents, or
 - c) improperly influence the EOI process
- 3.9.3 may result in rejection of the EOI Response and may render the entity ineligible for participation in future EOIs issued by MMGPA.

3.10 Confidentiality

- 3.10.1 Information submitted by EOI Respondents shall be treated as confidential to the extent permitted under applicable laws.
- 3.10.2 MMGPA may disclose such information where required by law, regulation, or directions of statutory or judicial authorities.

3.11 Governing Law

This EOI process shall be governed by and construed in accordance with the laws of India.

3.12 Respondents Information

Sr. No.	Document Name / Requirement	Description
1	Drug Manufacturing License	The manufacturing premises of the EOI Respondent 's products must comply with the requirements laid down under Schedule M of the Drugs and Cosmetics Rules, 1945. The EOI Respondent shall submit a valid compliance certificate/license issued by the State Licensing Authority unequivocally indicating Revised and upgraded Schedule M compliance as per GSR 922 (E), dated 28.12.2023. Attested photocopy of valid manufacturing drug license with product list approved by Central/State Licensing

Sr. No.	Document Name / Requirement	Description
		Authority for each and every product quoted as per technical specification in the bid. The license must have been duly renewed up to date and the items quoted shall be clearly highlighted in the license. If quoted item is manufactured at different places, Manufacturing License & Performance certificate from all such places from respective Licensing Authority/ State Drug Authority should be enclosed. However, Loan Licensee/ third party licensee are not allowed.
2	WHO-GMP Certificate	WHO-GMP certificate (with product list or COPP) clearly highlighting quoted products.
3	DCGI Permission	Copy of permission from DCGI for “New Drug & Fixed Dose Combination”.
4	Market Standing Certificate	Market Standing Certificate valid for a period of 5 years (i.e., for financial year 2021-22, 2022-23, 2023-24, 2024-25 & 2025-26) as a manufacturer/importer for each drug(s) quoted in the tender within the Bid Due date. The period of Market Standing will be reckoned from the date of issue of Product permission. In case of an importer, their principal manufacturer located overseas should have 5 years market standing in India and the importer shall have 5 years market standing in the pharmaceutical field. In cases involving new drugs/ drugs out of patent period it is sufficient to possess relevant market standing certificate, as applicable.
5	GST Registration	GST Registration certificate along with copy of last quarter.
6	Incorporation/Registration Certificate	Certificate of Incorporation / Registration of the EOI Respondent .
7	Authorization Letter	Authorization nominating responsible person to attend pre-bid/negotiation meetings.
8	Appendix-A	Schedule of Requirements.
9	Appendix-B	Checklist.
10	Annexure-1	Technical Specifications and Compliance.
11	Annexure-2	Letter Comprising Technical Bid.
12	Annexure-3	Proforma for Production and Sale Statement.
13	Annexure-4	Details of Manufacturing Unit.
13	Annexure-5	Details of Items Quoted with Drug Code.

Sr. No.	Document Name / Requirement	Description
15	Annexure-6	Annual Turnover Statement for three years (2022-23, 2023-24, and 2024-25) along with audited Balance Sheet & P&L Accounts for last 3 years certified by Statutory Auditor/Chartered Accountant with UDIN.
16	Annexure-7	Format of Power of Attorney for signing of Bid (not required for proprietorship).
17	Annexure-8	Affidavit for Non- Blacklisting.
18	Annexure-9	Litigation Affidavit.
19	Annexure-10	Mandate Form.
20	Schedule-4	Schedule for Packing of Drugs and Medicines.
21	Schedule-5	Bar Code & Advance Shipment Notification details.

3.13 Manufacturing/Importing and Product Permissions

- 3.13.1 EOI Respondents shall furnish details of their regulatory status as pharmaceutical manufacturers and/or importers licensed under the provisions of the Drugs and Cosmetics Act, 1940 and the rules made thereunder. Such details may include manufacturing licenses issued by the competent State Licensing Authority (SLA) and/or Central Licensing Authority (CLA), including licenses in Forms 25, 28, 28D, 28E, MD-5, and MD-9, as applicable to the drugs proposed, together with validity or retention particulars.
- 3.13.2 In the case of importers, Respondents shall furnish details of import licenses issued by the Drugs Controller General of India (DCGI), including Forms 10 or 10-A, along with relevant import registrations such as Form 41 or Form MD-15, and associated wholesale licenses such as Forms 20B and/or 21B, wherever applicable.
- 3.13.3 In respect of New Drugs and/or Fixed Dose Combinations, Respondents shall furnish details of import and/or manufacturing permissions obtained under the Drugs and Cosmetics Act, 1940 and the New Drugs and Clinical Trials Rules, 2019, including permissions such as Forms CT-20 and/or CT-23, where applicable.
- 3.13.4 In case of imported products, only one authorized importer per Original Manufacturer per product shall be permitted.
- 3.13.5 Respondents shall also indicate linkage between manufacturing/import approvals and supply capability, including delivery timelines.

3.14 Delivery Capability

- 3.14.1 EOI Respondents shall provide indicative details on:
- (a) production lead time,
 - (b) dispatch timeline,
 - (c) emergency supply capability,

- (d) monthly production capacity,
- (e) warehousing/logistics arrangements in Maharashtra.

3.15 Respondent Classification

3.15.1 EOI Respondents shall provide information on:

- (a) MSME status,
- (b) SC/ST ownership,
- (c) location – within Maharashtra / outside Maharashtra.

3.16 Eligibility Criteria

Sr.No.	Basic Requirement	Specific Requirement	Documents required
1	Registered Legal Entity	The EOI Respondent may be a company or a firm, registered under applicable laws in India (“Respondent”). The Respondent shall be – a. A Private Limited Company or a section 8 Company registered under the Companies Act 1956/2013, b. A Limited Liability Partnership under the Limited Liability Partnership Act 2008 c. Registered with the GST Authorities. d. Should have a valid PAN/TAN number. Proprietorship firms are not allowed to participate in this EOI.	Copy of certificate of incorporation/registration along with charter documents like copy of Memorandum and Articles of Association, and other registration documents according to the nature of entity. Copy of GST Registration certificate issued by GSTN authorities. Copy of PAN/TAN Card.
2	Licenses	The Respondent must have valid manufacturing license/import license for the drugs quoted as per technical specifications in the Tender Documents:	Self-attested copies of original manufacturing license in Form 25, 28, 28-D, 28-E, MD-5, MD-9 etc. approved by the Licensing authority along

Sr.No.	Basic Requirement	Specific Requirement	Documents required
		a. Only manufacturer/ importer (i.e., authorized agent/subsidiary of the foreign manufacturer) will be allowed as Bidder. b. Loan Licensee / third party licensee are not permitted to participate under this Tender Document.	with retention Licenses. Or Self-attested copies of original import license in Form-10 or Form 10-A (as applicable), Form-41, MD-15 etc., and licenses in Form 20B/21B approved by the corresponding licensing authority with retention licenses. Or Self-attested copies of licenses in Form CT-20, Form CT-23 in case of new drugs. Further, during supply of drugs, if the drugs are manufactured at more than one premises, the Bidder shall submit the applicable license such as the manufacturing license, for each such premises mandatorily. Authority letter of the original manufacturer for importing the product for which bid is offered or agreement between foreign manufacturer and importer. The drugs quoted shall be highlighted in the product permission with their respective drug code as mentioned in the Appendix-A (Schedule of Requirement)

Sr.No.	Basic Requirement	Specific Requirement	Documents required
3	Certifications/Registration	WHO-GMP (WHO - Good Manufacturing Practices Certificate) Certificate issued by the licensing authority. The WHO-GMP certificate must not be older than one year from the Bid Due Date in case where validity is not mentioned in the certificate. The WHO-GMP certificate of all the manufacturing plants, of which products have been quoted, should be submitted. The Importer should produce WHO-GMP / COPP of the manufacturing firm or a certificate which is at par with WHO-GMP issued by exporting countries like US-FDA approval, etc. In the case of imported drugs, labels and product literature of all quoted products must be submitted. The manufacturing premises of the Bidder's products must comply with the requirements laid down under Schedule M of the Drugs and Cosmetics Rules, 1945. The bidder shall submit a valid compliance certificate/license issued by the State Licensing Authority unequivocally indicating Revised and upgraded Schedule M compliance as per GSR 922 (E), dated 28.12.2023.	For manufacturers, WHO-GMP certificate with product list OR COPP, Quality management System (QMS) as per Medical Devices Rules, 2017 issued by the licensing authority wherever applicable. For importers, labels and product literature of all quoted drug(s) must be uploaded with WHO-GMP or certificate which is at par with WHO-GMP issued by the authorities of exporting countries of their principal manufacturing company or firm. Authority letter from OEM for the offered drug and valid import license issued by licensing authority. Import Export Certificate (IEC Code) for importer.
4	Past Experience	The Respondent must submit particulars of quantity of the past supplies of drugs made as per Annexure 3. Note: At least 80% quantity for similar drug as specified in the Schedule of	Certificate issued by a statutory auditor/chartered accountant (as attached Annexure-3)

Sr.No.	Basic Requirement	Specific Requirement	Documents required
		Requirements i.e. Appendix A' must have been supplied for any of the last 3 (three) financial years preceding the Bid Due Date, i.e., 2023-24, 2024- 25 & 2025-26. The Respondent shall submit the work done with satisfaction from the concerned authority. For the Purpose of quantification of 80% similar work only the Purchase order from Govt./Semi-Govt.& Hospitals registered under Maharashtra Public Trust Act 1950 shall be considered. Purchase Order from private hospitals shall not be considered.	
5	Average Annual Turnover	Average Annual Turnover (in last three financial years 2023-24, 2024- 25 & 2025-26. shall be as per mentioned in the Schedule of Requirements i.e. Appendix A.	Certificate issued by a statutory auditor/chartered accountant (as attached Annexure-6) along with audited financial statements confirming the average annual Turnover of the Bidder during the stated financial years must be submitted. The turnover should be as certified by the chartered accountant/statutory auditor (specifying UDIN) and having valid registration. Note: In case the annual accounts for the latest financial year are not audited and therefore the Bidder cannot make it available, the Bidder shall

Sr.No.	Basic Requirement	Specific Requirement	Documents required
			give an undertaking to this effect and the chartered accountant/statutory auditor shall certify the same. In such a case, the Bidder shall provide the audited financial statements for the financial year preceding the latest financial year for which the audited annual report is not being provided.
6	Net Worth	The net worth of the Bidder in the financial year immediately preceding the Bid Due date should be positive and should have not eroded by more than 30% (thirty percent) in the last three (3) years.	Certificate issued by a statutory auditor/chartered accountant (as attached Annexure-6). The Net Worth should be as certified by the chartered accountant/ statutory auditor (specifying UDIN) and having valid registration.
7	Production Capacity	Production capacity of the original drug manufacturer must be minimum Two (2) times of the quoted order quantity in last one financial year.	Certificate of Statutory Auditor/Chartered Accountant. As per Annexure 4.
8	Market Standing Certificate	Bidder should mandatorily possess 5 years Market Standing Certificate (i.e., for financial year (2021-22, 2022-23, 2023-24, 2024-25 & 2025-26) as a manufacturer/importer for each drug(s) quoted in the tender as on Bid Due Date. The period of Market Standing will be reckoned from the date of issue of product/drug permission.	Market Standing Certificate as issued by Central or State Licensing Authority under the Applicable Law. Bill of landing of a foreign manufacturer and bill of entry of the importer, mentioning the country of

Sr.No.	Basic Requirement	Specific Requirement	Documents required
		In case of an importer, their principal manufacturer located overseas should have 5 years market standing in India and the importer shall have 5 years market standing in the pharmaceutical field. In cases involving new drugs/ drugs out of patent period it is sufficient to possess relevant market standing as applicable.	origin. Notarized/ certified copy of Drug Controller General of India, new Delhi, for permission for Items coming under, “New Drug and Fixed Dose Combinations” in form 45/46 as per Drugs & Cosmetic Act and Rules. Relevant period Market standing certificate for new drug/drugs out of patent period issued by licensing authority.
9	Proof of distribution network	Bidders, if not having their registered office, manufacturing unit, or distribution facility within Maharashtra State, must have an established and operational distribution network in Maharashtra State at the time of EOI submission. In case there is no registered office or established operational distribution network the respondent/bidder shall give undertaking for establishment of both within three (3) months from the last date of submission of EOI.	Proof of distribution network— such as a valid drug selling/distribution license issued by the state’s licensing authority, along with details of authorized distributors (names, addresses, contact details) must be submitted as part of the bid documentation Annexure 4 (A) and Copy of License of Sale / Distribution issued by State’s Licensing Authority
10	Blacklisting or banned	On the Bid Due Date, the Bidder should not be blacklisted or debarred by any ministry/department /attached offices/sub-ordinate offices under Government of	Affidavit as per Annexure 8

Sr.No.	Basic Requirement	Specific Requirement	Documents required
		India and any State government, Autonomous bodies (established by Central/State govt), any Central/State PSUs for unsatisfactory past performance, corrupt, fraudulent or any other Fraudulent and Corrupt business practices. The bidder, whose drug has been declared as misbranded, spurious or adulterated or any criminal case in respect of the above is pending in any court, as on Bid Due Date shall not be eligible to participate for that particular drug, in the bid. Similarly, a Bidder convicted by court of law shall not be eligible to participate in the bid.	
11	Non-Conviction Certificate	The Tenderer(s) quoting for this tender shall not have been convicted by any Court of Law in India/overseas in lieu of deficiency noticed in the any of the quoted Product(s) in the tender and tender should not be submitted for such products for which conviction was granted by any Court of Law for a period of Three years from date of such order(s).	Non-Conviction certificate Issued by licensing authority/State FDA.
12	Litigation	The Bidder should not be involved in any major litigation such as fraud, FEMA violations and any other civil or criminal proceedings that may have an impact of	Affidavit as per Annexure 9.

Sr.No.	Basic Requirement	Specific Requirement	Documents required
		affecting or compromising the delivery of services as required under this contract.	
13	Conflict of Interest	On the date of submission of the Bid, the Bidder should not have any conflict-of-interest situation.	Undertaking by the authorized signatory as per Annexure 2
14	Quantity specified in EOI	The quantity mentioned in the EOI is indicative in nature. Detail requirement will be given in subsequent RFP.	-

Appendix A: Schedule of Requirements

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
1	Amoxicillin + Clavulanic Acid Susp	Each 5ml Of Reconstituted Suspension to contains: Amoxicillin Trihydrate IP Equivalent to Amoxicillin 125mg, Potassium Clavulanate Diluted IP Equivalent to Clavulanic Acid 31.25mg 30ml bottle	Syrup	70875	1255905
2	Amoxicillin powder for suspension 125 mg/5 ml	Susp. Amoxycillin Trihydrate 125 mg / 5 ml., Bottle of 60 ml	Syrup	14408550	253590480
3	Amoxycillin + Clavulanic acid Dry Syrup 30ml	Amoxycillin 200 mg + Clavulinic acid 28.5 mg /5ml Dry Syrup 30ml Bottle	Syrup	40050	709686
4	Amoxycillin 125mg + Clavulanic acid 31.25mg/5ml Dry syrup)	Amoxycillin 125mg + Clavulanic acid 31.25mg/5ml Dry syrup, 30 ml Bottle	Syrup	10915830	162427550
5	Amoxycillin Syrup 125mg, 60ml Bottle	Sy. Amoxycillin Trihydrate 125 mg / 5 ml, Bottle of 60 ml	Syrup	9686475	119492356
6	Amoxycillin Syrup 250mg, 60ml Bottle	Sy. Amoxycillin Trihydrate 250 mg / 5 ml, Bottle of 60 ml	Syrup	4859190	81245657
7	Anesthetic Antacid Gel 200ml bottle	each 5ml contain Dried Aluminum Hydroxide 291mg Magnesium hydroxide 98mg Oxetacaine 10mg 200ml bottle	Syrup	6975	135594
8	Antacid Suspension	Antacid Suspension Each 5 ml contains Aluminum Hydroxide 250mg Magnesium Hydroxide 250mg Dimethicone 50mg Suspension OR Equivalent 210 ml. Bottle	Syrup	92250	2187078
9	Artemether (A) + Lumefantrine (B) Oral Liquid 80mg+480mg/5ml	Artemether (A) + Lumefantrine (B) oral liquid 80mg+480mg/5ml contains Each 5ml reconstituted Artemether (A) + Lumefantrine (B) oral liquid 80mg+480mg, Excipients q.s., 30 ml Bottle	Syrup	1000	15200
10	Azithromycin Syrup 200mg/5ml, 15ml	Azithromycin 200mg/5ml Syrup 15ml Bottle	Syrup	9336960	113985608
11	Azithromycin Syrup 100 mg /5 ml 15ml bottle	Azithromycin 100mg/5ml Syrup 15ml Bottle	Syrup	10238	115577
12	Azithromycin Syrup 200mg/5ml 30ml bottle	Azithromycin 200mg/5ml Syrup 30 ml bottle	Syrup	2250	32184
13	Bromhexine Hydrochloride Syrup 100 ml	Bromhexine Hydrochloride Syrup 100 ml Contains Bromhexine Hydrochloride 4mg/5ml, 100 ml	Syrup	5489100	84532140

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
14	Calcium Syrup with Vit. D3 & B12	Calcium Syrup with Vitamin D3 & B12 Each 5 ml contains Calcium Gluconate 1.18 gm Calcium Lactobionate USP 260 mg, Vit. B12 (Cyanocobalamin) I.P. 1.5 mcg Vit. D3 (Cholecalciferol) I.P. 100 I.U. OR Equivalent 200ml Bottle	Syrup	13613	299475
15	Calcium with Phosphate Syrup	Each 5ml to contain: Vit. D3-200 IU, Vit. B12-2.5 mcg., Calcium with Phosphate -82 mg 200ml Bottle	Syrup	8100	170424
16	Carbamazepine Oral Liquid, 100 mg/5ml	Syrup Carbamazepine 100 mg per 5 ml, 100 ml Bottle	Syrup	13824	243302
17	Carbamazepine Syrup 200mg/5ml, 100ml Bottle	Syrup Carbamazepine 200 mg per 5 ml, 100 ml Bottle	Syrup	283824	3632947
18	Cefadroxil Oral Liquid 125 mg/5 ml	Cefadroxil Oral Liquid 125 mg/5 ml contains; Cefadroxil Monohydrate IP equivalent to Anhydrous Cefadroxil 125mg/5 ml, Bottle of 30 ml	Syrup	278910	3346920
19	Cefixime 100mg/5ml Syrup 60ml	Cefixime 100mg/5ml Syrup 60ml	Syrup	1575	30568
20	Cefixime 50mg/5ml Oral Suspension 30ml bottle	Cefixime 50mg/5ml Oral Suspension 30ml bottle For pediatric use	Syrup	3375	75600
21	Cefixime 50mg/5ml Syrup 60ml	Cefixime 50mg/5ml Syrup 60ml	Syrup	16200	208915
22	Cefixime Oral Liquid 100 mg/5 ml	Cefixime Oral Liquid 100 mg/5 ml, 30 ml Bottle	Syrup	2766150	28767960
23	Cefixime Oral Liquid 50 mg/5ml	Cefixime Oral Liquid 50 mg/5ml, 30 ml Bottle	Syrup	1183410	8615225
24	Cetirizine Syrup 30ml	Cetirizine Syrup 5 mg/5 ml, 30 ml Bottle	Syrup	23374944	170730591
25	Chloroquine Syrup 50mg/5ml, 60ml Bottle	Chloroquine Syrup 50mg/5ml, 60ml Bottle	Syrup	176202	2664174
26	Chlorpheniramine Maleate Syrup 100 ml	Syrup Chlorpheniramine Maleate Each 5ml contain Pheniramine Maleate 2 mg - 100 ml	Syrup	7332390	41530657
27	Ciprofloxacin Oral Liquid 250 mg/5ml	Ciprofloxacin Oral Liquid 250 mg/5ml, 60 ml Bottle	Syrup	271782	3478810
28	Clarithromycin Oral Liquid 125mg/5ml	Clarithromycin Oral Liquid 125mg/5ml, 30 ml Bottle	Syrup	2972	166446

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
29	Codeine Oral Solution 15 mg/5ml	Codeine Oral Solution 15 mg/5ml contains Codeine Phosphate 15 mg/5ml & Guaifenesin 100 mg, 118 ml Bottle	Syrup	1000	48000
30	Co-trimoxazole Syrup 50ml Bottle	Co-trimoxazole Syrup contains Trimethoprim 40mg + Sulphamethoxazole 200mg/5ml 50ml Bottle	Syrup	1422383	15646208
31	Cough Expectorant with Dextromethorphan Hydrobromide 100ml Bottle	Cough Expectorant with Dextromethorphan Hydrobromide Each 10ml Contains Dextromethorphan Hydrobromide I.P. 10mg, Chlorpheniramine Maleate I.P. 4mg, Guaifenesin I.P. 100mg, Alcohol (95%) 0.2ml, OR Equivalent 100ml Bottle	Syrup	398025	7935026
32	Cough Linctus: Noscipine+Citric acid+Sod Citrate Pediatric Syrup	Each ml to contain : Noscipine 1.83mg, Citric Acid 5.8mg, Sod. Citrate 0.67mg, Amm. Chloride 7mg	syrup	9000	187200
33	Cough Suppressant with Diphenhydramine & Guaifenesin 100 ml Bottle	Cough Suppressant with Diphenhydramine & Guaifenesin Each 5 ml contains Diphenhydramine HCL IP 8 mg, Guaifenesin IP 50 mg, Bromhexine HCL IP 4mg, OR Equivalent 100ml Bottle	Syrup	126000	1195488
34	Cough Syrup Terbutaline + Guaifenesin + Ambroxol 100ml Bottle	Each 5 ml to contain: Terbutaline I.P 1.25mg + Guaifenesin I.P 50mg + Ambroxol I.P 15mg Syrup Base QS	Syrup	12600	232546
35	Cough Syrup: Bromhexine Hcl 4mg 100ml	Each 5ml to contain: Bromhexine Hcl. 4mg 100ml bottle	Syrup	33300	346586
36	Cough Syrup (HBPCCL Reserved) 100ml Bottle	Each 5 ml Contains Diphenhydramine 15 mg, Ammonium chloride 150 mg, Sodium citrate 60 mg, Menthol 1 mg, and Flavoured Base Colour : Ponceau 4 R Or Equivalent 100ml Bottle	Syrup	83250	1846152
37	Cough Syrup: Ambroxol and Terbutaline	Each 5 ml to contain: Ambroxol Hydrochloride IP 30 mg, Terbutaline Sulphate IP Equivalent to Terbutaline 2.50 mg, Guaifenesin IP 50 mg, Menthol IP 0.5 mg 100ml bottle	Syrup	2250	58698
38	Cough Syrup: CPM+Codeine Linctus Syrup 100ml	Each 5ml to contain: Chlorpheniramine Maleate 4mg, Codeine Phosphate 10mg 100ml bottle	Syrup	29250	741780
39	Desflurane 240ml Bottle	Desflurane Liquid for inhalation 240ml Bottle	Syrup	1103	7765349
40	Dextromethorphan Oral Syrup 60 ml	Each 5 ml contains; Dextromethorphan Hydrobromide IP 10 mg, Chlorpheniramine Maleate IP 2 mg, Phenylephrine Hydrochloride IP 5. mg, Flavoured Syrupy Base q.s. 60 ml Bottle	Syrup	60021891	2881050768

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
41	Dicyclomine Hcl and Dimethicone Syrup	Each ml to contain: Dicyclomine Hcl 10 mg, Activated Dimethicone 40mg Syrup 30ml bottle	Syrup	2700	34387
42	Diethyl ether Anesthetic in Amber coloured bottle rapped in photo resistant black paper I.P 500 ml Bottle	Diethyl ether Anesthetic in Amber coloured bottle rapped in photo resistant black paper I.P 500 ml Bottle	Syrup	1000	186880
43	Diethylcarbamazine Citrate Oral Liquid 100 ml	Each 5ml Contains Diethylcarbamazine Citrate 120/5ml 100ml Bottle	Syrup	120933	2031674
44	Disodium Hydrogen Citrate Syrup	Each 5ml contains Disodium Hydrogen Citrate 1.25gm 100 ml bottle	Syrup	38250	987156
45	Domperidone 1mg/ml Suspension 30ml bottle	Domperidone 1mg/ml Suspension 30ml bottle	Syrup	4275	17613
46	Domperidone Oral Liquid 1 mg/ml	Syrup Domperidone Sy. Domperidone 1 mg / ml - Bottle of 30 ml	Syrup	1447740	5362429
47	Doxycycline Syrup 50 mg/5ml	Doxycycline Syrup 50 mg/5ml contains; Doxycycline (Anhydrous) 50mg, Flavoured Syrup Base q.s., 15gm/60 ml Bottle	Syrup	270891	4767682
48	Erythromycin Stearate 125mg/5ml Dry Syrup 60ml Bottle	Erythromycin Stearate 125mg/5ml Dry Syrup 60ml Bottle	Syrup	1000	14400
49	Fluconazole 100ml bottle	Fluconazole 2 mg/ml 100ml bottle	Syrup	17888	489402
50	Furazolidone 25mg/5ml, 60 ml Bottle	Sy. Furazolidine 25 mg / 5 ml : 60 ml.	Syrup	7323750	36794520
51	Gama Benzene Hexachloride 1% w/w Lotion 100ml Bottle	Gama Benzene Hexachloride 1% w/w Lotion 100ml Bottle	Syrup	2250	45198
52	Hydroxyzine Syrup 10 mg/5ml	Hydroxyzine Syrup 10 mg/5ml	Syrup	61101	2688444
53	Ibuprofen Syrup 60ml Bottle	Ibuprofen 100mg/5ml, Bottle of 60ml	Syrup	6562125	38795283
54	IFA Syrup with Auto Dispenser 50 ml Bottle (Iron folic acid)	IFA Syrup with Auto Dispenser 50 ml Bottle	Syrup	20482200	132233083
55	Iron & Folic acid with Auto	Each 1ml of IFA Syrup should contain 20mg of elemental Iron and 100mcg of Folic Acid 50ml Bottle	Syrup	1575	15763

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
	dispensar syrup 50ml bottle				
56	Iron and Vitamin Drops (Paediatric)	Each 5ml Contains: Colloidal Iron equivalent to Elemental Iron 80mg Folic Acid IP 200mcg Vitamin B 12 IP 2mcg	syrup	5625	180000
57	Iron Folic Acid Drops Each ml Contains: Ferrous Fumarate IP Equivalent to elemental Iron 20mg, Folic Acid IP 100mcg, Vitamin B12 IP 5mcg OR Equivalent 20ml bottle	Iron Folic Acid Drops Each ml Contains: Ferrous Fumarate IP Equivalent to elemental Iron 20mg, Folic Acid IP 100mcg, Vitamin B12 IP 5mcg OR Equivalent 20ml bottle	Syrup	13613	86249
58	Iron Folic Acid Liquid 200ml	Each 15 ml contains; Protein Hydrosylate (Nitrogen content 20%) 1gm, Carbohydrate 6 gm, Elemental Iron (as Choline Citrate) 13 mg, Thiamine Hydrochloride IP 1 mg, Riboflavin Sodium Phosphate IP, equivalent to Riboflavin 0.5 mg, Pyridoxine Hydrochloride IP 0.5 mg, Cyanocobalamine IP 0.5 mcg, D-Panthenol IP 2.5 mg, Magnesium Chloride IP 10 mg, Manganese Chloride 0.1 mg, Niacinamide IP 10 mg, flavoured syrup base q.s.	Syrup	4363470	266241486
59	Isoniazid Oral Liquid 100 mg/5ml	Syp. Isoniazid 100mg/5ml, 100 ml Bottle	Syrup	12933	553532
60	Lactulose Solution 100ml bottle	Lactulose Solution contains lactulose 667mg/mL (10g/15mL) 100ml bottle	Syrup	2290678	153475409
61	Lactulose Syrup 250ml bottle	Lactulose Syrup Each 15 ml contains:- Lactulose Concentrate equivalent to Lactulose U.S.P. 10 gm 250ml bottle	Syrup	41738	3278230
62	Laxative Liquid	Each 5 ml to contain: Liquid Paraffin 1.25ml, Milk of Magnesia 3.75ml, Sodium Picosulphate 3.33mg. 200ml bottle	Syrup	6750	229824
63	Levetiracetam 100mg/ml Syrup 100ml bottle	Levetiracetam 100mg/ml Syrup 100ml bottle	Syrup	12600	4455360
64	Liver Tonic Choline with Methionine Liquid 200ml	Each 15ml contains: DL-Methionine BP 100.0mg Choline Dihydrogen Citrate NFXII 100.0mg L-Isoleucine USP 10.0mg L-Leucine USP 19.0mg L-Valine USP 11.0mg Pyridoxine Hydrochloride IP 1.50mg Nicotinamide IP 22.50mg Biotin USP 0.10mg Folic Acid IP 0.50mg Cyanocobalamin IP 3.0mcg Inositol BP 50.0mg	Syrup	2250	150354

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
65	Metronidazole 200mg/5ml Suspension 60ml Bottle	Metronidazole 200mg/5ml Suspension 60ml Bottle	Syrup	10575	99236
66	Metronidazole Susp. 200mg/5ml, 60ml Bottle	Metronidazole Suspension 200mg/ 5ml	Syrup	12011355	93976842
67	Montelukast syrup	Montelukast 4mg/5ml Syrup 50 ml Bottle	Syrup	1988955	668289
68	Multivitamin & Multimineral Elixir Syrup	Each 5ml contains Iodised Peptone 0.322mg(eq.to 33mcg iodine), Magnesium Chloride IP 6.67mg(eq. to 0.8 mg magnesium), Manganese Sulphate BP 1.33mg(eq. to 0.33 mg manganese), Sodium Metavanadate 0.22mg, Zinc Sulphate IP 10.71mg(equivalent to 2.5mg zinc), Pyridoxine Hydrochloride IP 0.25mg, Cyanocobalamin IP 0.167 mcg, Nicotinamide IP 3.33mg, Ethanol 95% IP 0.317ml.	Syrup	1575	128520
69	Multivitamin Drop Paediatric 15ml	Each ml to contain: Vitamin A Concentrate (As Palmitate) Oily Form: 3000 IU, Cholecalciferol 400 IU, Ascorbic Acid 40mg, Thiamine Mononitrate: 2mg, Riboflavin Sodium Phosphate Eqv To Riboflavin: 1mg, Nicotinamide 10.5mg, Pyridoxine Hydrochloride: 1mg, D. Panthenol 3mg, Tocopheryl Acetate 5.25IU, Flavoured Aqueous Base (Appropriate Overages Of Vitamins Added To Compensate For Loss On Storage)	Syrup	2700	36763
70	Multivitamin Drop with Zinc, 15 ml Drops	Each 15 ml contains; Cholecalciferol IP 200 IU Pyridoxine Hydrochloride IP 1 mg Niacinamide IP 15 mg Cyanocobalamin IP 1 mcg Zinc (as Zinc Gluconate USP) 3 mg B- Carotene Dispersion 2.5% USP 38 mg Manganese 0.8 mg Molybdenum 8 mcg Selenium (as sodium selenate) 10 mcg Lysine Hydrochloride USP 30 mg Iodine (as potassium iodide) 50 mcg Biotin USP 10 mcg Chromium 10 mcg Inositol 10 mg Lycopene USP (10%) 500 mcg	Syrup	15662700	375904800
71	Multivitamin Drops 20ml	Each ml Contains: Vitamin A (as Palmitate) IP 2500 I.U., Vitamin E I.P. 2.5 IU, Cholecalciferol I.P. 200 I.U., Thiamine Hydrochloride I.P. 1mg, Riboflavin (B2) I.P. 1mg, Pyridoxine Hydrochloride I.P. 0.5 mg,	Syrup	3375	67554

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
		Niacinamide I.P. 10mg, Ascorbic Acid I.P 40 mg, D Panthenol I.P 1 mg, Zinc Sulphate I.P 13.3 mg, Lysine HCL U.S.P. 10 mg, Color : Caramel OR Equivalent 20ml bottle with dropper			
72	Multivitamin Syrup (For Therapeutic use only) 100ml bottle	(For Therapeutic use only) Each 5ml contains Vitamin A Palmitate BP 3000 IU Cholecalciferol BP 400 IU Thaimine Hydrochloride BP 2.5 mg Riboflovine BP 2.5 mg Ascorbic Acid BP 50 mg Nicotinamide BP 25 mg Pyridoxine Hydrochloride BP 1 mg Cyanocobalamin BP 3 mcg D-panthenol BP 5mg Flavoured Syrupy base QS Excipients QS	Syrup	15300	514080
73	Multivitamin Syrup (For Therapeutic use only) 200ml	(For Therapeutic use only) Each 5ml contains Vitamin A Palmitate BP 3000 IU Cholecalciferol BP 400 IU Thaimine Hydrochloride BP 2.5 mg Riboflovine BP 2.5 mg Ascorbic Acid BP 50 mg Nicotinamide BP 25 mg Pyridoxine Hydrochloride BP 1 mg Cyanocobalamin BP 3 mcg D-panthenol BP 5mg Flavoured Syrupy base QS Excipients QS	Syrup	5400	362880
74	Multivitamin with Zinc 15ml drops	Each 1 ml contains Vitamin A Concentrate (Oily form) IP. (as palmitate) 2500 IU Thaimine Hydrochloride IP. 0.5 MG Riboflavine IP (as riboflavine sodium phosphate IP) 0.5 mg Pyridoxine Hydrochloride IP. 0.5mg D-Panthenol IP. 1.5 MG Cholecalciferol IP (Vitamin D3) 200 IU Nicotinamide IP 5mg Ascorbic Acid IP 25 mg Vitamin E Acetate IP 2.5 IU Zinc Sulphate IP (eq. to elemental zinc 2.5 mg) 11 mg Flavour: pineapple Orange Flavour In flavoured aqueous vehicle appropriate overages of vitamins added to compensate for loss on storage.	Syrup	5625	175500
75	Norfloxacin Oral Liquid	Norfloxacin Oral Liquid 100mg/ml, 60 ml Bottle	Syrup	271782	71750
76	Omega-3 Emulsified Fruity Flavour Patented Syrup 150 ml	Each 10 ml Contains Total Omega-3 (500 mg), EPA-250 mg , DHA- 190 mg , 150 ml Bottle	Syrup	1000	559200
77	Omega-3 veg drop 30 ml Bottle	Each ml Contains Total Omega-3 (200 mg), EPA-50 mg , DHA- 100 mg , 30 ml Bottle	Syrup	1000	448000
78	Ondansetron 2mg/5ml Syrup 30ml bottle	Ondansetron 2mg/5ml Syrup 30ml bottle	Syrup	9298616	43629104
79	Oral Liquid Levocetirizine 2.5 mg	Each 5 ml contains: Levocetirizine Dihydrochloride 2.5 mg, 60 ml Bottle	Syrup	1080000	12096000

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
80	Oseltamivir 12mg/ml Oral Suspension 75ml bottle	Oseltamivir 12mg/ml Oral Suspension 75ml bottle	Syrup	1598	455479
81	Paracetamol (Acetaminophen) Syrup 120 mg/5ml, 60ml bottle	Paracetamol (Acetaminophen) Syrup 120 mg/5ml, 60ml bottle	Syrup	356400	6968333
82	Paracetamol 125mg/5ml Syrup 60ml Bottle	Paracetamol 125mg/5ml Syrup 60ml Bottle	Syrup	107775	2107217
83	Paracetamol 250mg/5ml Syrup 60ml Bottle	Paracetamol 250mg/5ml Syrup 60ml Bottle	Syrup	183375	1582893
84	Paracetamol Syrup 60ml Bottle	Sy. Paracetamol 250 mg/5 ml Bottle of 60 ml	Syrup	48791700	910648289
85	Pheniramine Maleate 5ml/5ml Syrup	Syrup Chlorpheniramine Maleate Each 5ml contain Pheniramine Maleate 2 mg - 100 ml	Syrup	332910	8764854
86	Phenobarbitone sodium Syrup 60ml bottle	Phenobarbitone sodium 20mg/5ml Syrup 60ml bottle	Syrup	11925	412128
87	Phenobarbitone Syrup 20mg/5ml, 60ml Bottle	Phenobarbitone Syrup 20mg/5ml, 60ml Bottle	Syrup	66933	1713485
88	Potassium Chloride Oral Solution 100 ml	Each 5 ml contain 1.5 gm 100 ml Bottle	Syrup	4118	177876
89	Potassium Chloride Syrup 400ml Bottle	Potassium Chloride 1.5gm/10ml Syrup 400ml Bottle	Syrup	1238	66092
90	Prednisolone Acetate Ophthalmic Suspension 1%	Prednisolone Acetate Ophthalmic Suspension 1%	Syrup	76491	1223856
91	Pregabalin Syrup 50mg/ml	Pregabalin Syrup 50mg/ml	Syrup	1000	32000
92	Promethazine Syrup 60ml Bottle	Promethazine 5mg/5ml Syrup 60ml Bottle	Syrup	9000	59616
93	Protein & Iron Syrup 100ml	Each 5ml contains peptonised iron 176.5mg (eq to 30mg elemental iron),protein as peptone 100mg,folic acid 200mcg,vitam B12 2.5mcg	Syrup	1000	91360
94	Rifampicin Oral Liquid 100 mg/5 ml	Rifampicin Oral Liquid 100 mg/5 ml, 200 ml Bottle	Syrup	12933	124157
95	Salbutamol Syrup 100ml bottle	Salbutamol 2mg/5ml Syrup 100ml bottle	Syrup	1125	12096

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
96	Salbutamol Syrup 2mg/5ml, 100ml Bottle	Salbutamol Syrup 2mg/5ml, 100ml Bottle	Syrup	2295540	28281053
97	Sodium Valproate Syrup 200mg/5ml	Valproate Sodium 200 mg/5ml Syrup 100ml bottle	Syrup	55454	910103
98	Sucralfate Suspension 100ml bottle	Sucralfate Suspension 100ml bottle	Syrup	42998	1078721
99	Sucralfate Oral Suspension 1gm, 100ml Bottle	Sucralfate Oral Suspension 1gm Each 10ml Contains Sucralfate 1000mg	Syrup	548910	21569967
100	Syrup Calcium with Phosphate in the ratio 2:1 with Vitamin D, 100 ml	Each 5 ml contains: Vitamin D3 (cholecalciferol) I.P. 200 IU, Vitamin B12 (Cynocobalamin) I.P. 2.5mcg, Calcium phosphate 82mg, 100 ml Bottle	Syrup	21341475	563414940
101	Topical anaesthetic spray	Should contain topical anaesthetic lignocaine in a metal packed bottle. Should follow ISO/ISI standards	Syrup	1000	259200
102	Vitamin A Concentrated Solution 100ml	Concentrated Vitamin A solution I P 1,00,000 I U Each ml contains Vitamin A I P Synthetic equivalent to about 109500 I U/gm - Bottle of 100 ml with Dropped marked for doses	Syrup	588762	62908042
103	Vitamin A Solution I.P. Concentrated 100,000 I.U. 100ml Bottle with dropper marked for doses	Vitamin A Solution I.P. Concentrated 100,000 I.U. 100ml Bottle with dropper marked for doses	Syrup	1000	70963
104	Vitamin and Protein Syrup	Each 15ml contains Protein Hydrolysate, Nitrogen Content 20% 1.0gm, Carbohydrate I.P. 6.0gm, Elemental Iron (as choline citrate) 13.0mg, Thiamine Hydrochloride I.P. 1.0mg, Riboflavin Sodium Phosphate I.P. Equivalent to Riboflavin 0.5mg, Pyridoxine Hydrochloride I.P. 0.5mg, Cynocobalamin I.P. 0.5 mcg, D-Pantheol I.P. 2.5 mg, Magnesium Chloride I.P. 10 mg, Magnese Chloride I.P. 0.1 mg, Niacinamide I.P. 10 mg, Flavoured syrup Base Q.S OR Equivalent 200 mlBottle	Syrup	4500	249084
105	Vitamin B Complex Syrup	Each 5ml to contain: Vit. A 2500 IU, Cholecalciferol 200 IU, Thiamine 2mg, Riboflavin 1mg, Pyridoxine 1mg, Nicotinamide 15mg, Ascorbic Acid 50 mg, D -Panthenol 2.5mg, Cyanocobalamin 1mcg, Citrus Bioflavonoid Compound 5mg	Syrup	13613	831996
106	Vitamin D Drops 50 mg/ml, 30 ml Bottle	Each ml contains ; Cholecalciferol IP 400 IU (Vitamin D3) (as stabilized) in a flavoured syrupy base q.s.	Syrup	6122250	122445000
107	Zinc sulphate or gluconate Syrup 50ml bottle	Zinc sulphate or gluconate Syrup : Each 5ml of syrup contains Zinc Sulphate or gluconate equivalent to Elemental Zinc 20mg 50ml bottle	Syrup	20250	119151

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
108	Zinc Sulphate or Gluconate Syrup 60ml Bottle	Zinc sulphate or gluconate Syrup : Each 5 ml of Syrup contains Zinc Sulphate or gluconate equivalent to Elemental Zinc 20mg.	Syrup	2626425	12663571
109	Activated Charcoal Oral	Activated charcoal/Magnesium hydroxide, 500 gm Jar/ Bottle	Oral	66933	401598
110	Amino Acid Granules	Each 10g Sachet to contain: L-Valine USP 1144mg, L-Isoleucine USP 952mg, L-Leucine USP 1904mg	Oral	11250	1094400
111	Budesonide 160mcg & Formoterol 4.5mcg Inhalation aerosol	Each Inhaler contains Budesonide 160mcg & Formoterol 4.5mcg Inhalation aerosol 120 inhalations	Oral	2475	768240
112	Budesonide 200mcg + Formoterol Fumarate 6mcg Inhaler	Budesonide 200mcg + Formoterol Fumarate 6mcg Inhaler	Oral	1000	107240
113	Budesonide 320mcg + Formoterol 9mcg Inhalation	Each Inhaler contains Budesonide 320mcg + Formoterol 9mcg Inhalation	Oral	1000	366400
114	Budesonide 80mcg & Formoterol 4.5mcg Inhalation aerosol	Budesonide 80mcg & Formoterol 4.5mcg Inhalation aerosol 120 inhalations	Oral	1000	240000
115	Budesonide Inhalation (MDI/DPI) 200 mcg/dose	Budesonide Inhalation (MDI/DPI) 200 mcg/dose	Oral	1000	64000
116	budesonide Inhalation (MDI/DPI) 200mcg (A) + 6mcg (B)	BUDESONIDE 200 mcg. + FORMOTEROL 6 mcg., INHALER 120 MDI	Oral	270891	433426
117	Budesonide Inhalation (MDI/DPI)100mcg/dose	Budesonide Inhalation (MDI/DPI)100mcg/dose	Oral	270891	13002768
118	Budesonide Inhaler 200 mcg	Budesonide Inhaler 200 mcg	Oral	1350	200880
119	Budesonide Nebulisation Solution	Budesonide BP 0.5 mg Nebulisation Solution	Oral	304911	1463573
120	Budesonide Resp. Solution 0.5mg	Budesonide Resp. Solution 0.5mg/ 2ml Respule	Oral	46791	524059
121	Budesonide Respirator Solution for use in Nebuliser 1mg/ml	Budesonide Respirator Solution for use in Nebuliser 1mg/ml	Oral	19791	142495

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
122	Caffeine Oral liquid 20 mg/ml	Syp. Caffeine Citrate 20mg/ml, Contains Caffeine Citrate 20 mg/ ml (equivalent to 10 mg caffeine base/ ml).	Oral	38691	9007265
123	Calamine Lotion Bottle 50ml I.P	Calamine 8% w/v, Diphenhydramine hcl 1% w/v, Camphor 0.1% w/v, specially Denatured Spirit 2.37% v/v	Oral	3583035	50334476
124	Calamine Lotion I.P 100ml Bottle	Calamine Lotion I.P 100ml	Oral	4500	70200
125	Calcium with Vitamin D3 Granules	Sachet Elemental Calcium with Vitamin D3 Granules Each Sachet contains : From an organic source (Oyster shell) Equivalent to Elemental Calcium 500mg + Vitamin D3 IP 250 IU OR EQUIVALENT	Oral	2250	18900
126	Chlorpheniramine Oral Liquid 5 mg/5 ml	Chlorpheniramine Oral Liquid 5 mg/5 ml	Oral	65691	462465
127	Cholecalciferol 60000 IU Granules Sachet	Vitamin D3 (Cholecalciferol) 60,000 IU/g Granules Sachet	Oral	18608400	44064691
128	Cholecalciferol Drops	Each ml to contain: Cholecalciferol 400IU/ml	Oral	5625	48375
129	Clotrimazole Oral Solution	Clotrimazole Oral Solution [IPHS197]	Oral	86546	5538960
130	Cloxacillin Oral Liquid 125 mg/5ml	Cloxacillin Oral Liquid 125 mg/5ml	Oral	1782	11405
131	Combination of LABA+ICS (Formoterol, Salmeterolol/Fluticasone)MDI,DPI	Combination of LABA+ICS (Formoterol, Salmeterolol/Fluticasone)MDI,DPI	Oral	1000	72000
132	Cyclosporine Oral Liquid 100mg/ml	Cyclosporine Oral Liquid 100mg/ml	Oral	1000	200000
133	Dextrose Monohydrate I.P. 500gm packet	Dextrose Monohydrate I.P. 500gm packet	Oral	1000	49000
134	Diazepam oral liquid 2mg/5ml	Diazepam oral liquid 2mg/5ml contains Each 5 ml 5 mg of Diazepam	Oral	54891	614779
135	Diazepam Suppository 5mg	Diazepam Suppository 5mg	Oral	1000	4960
136	Dicyclomine Hydrochloride and Simethicone Oral Drops 10ml	Each ml contains Dicyclomine hydrochloride 10 mg and Simethicone 40 mg	Oral	2250	20700

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
137	Ferrous Salt (A) + Folic Acid (B) oral liquid 20 mg elemental iron (A) +500 mcg (B)as enteric coated	Ferrous Salt (A) + Folic Acid (B) Oral Liquid 20 mg Elemental Iron (A) +500 mcg (B)as enteric coated	Oral	7830000	4836434
138	Ferrous Salts Oral liquid Equivalent to 25mg of Elemental Iron/ml	Ferrous salts Oral liquid Equivalent to 25mg of elemental iron/ml	Oral	1000	37600
139	Glucose Powder 75 gm	Indian Standard IS 874:1992 Dextrose Monohydrate (3rd Revision) Sachet of 75 gm	Oral	16819731	161469418
140	Glutamine solution 20% 100 ml Bot.	Glutamine solution 20%containing Dipeptide N-2-L Alanyl-Glutamine . (Only For Septicemic Shock Use)100 ml Bot.	Oral	1000	692000
141	Ipratropium + Levosalbutamol Nebulisation Solution	Ipratropium 500 mcg + Levosalbutamol 1.25 mg Nebulisation Solution Respules, 2.5 ml Ampoule	Oral	18900	166320
142	Ipratropium Inhalation (MDI/DPI) 20mcg/dose	Ipratropium bromide 20mcg/Dose (MDI/DPI)	Oral	1000	48000
143	Ipratropium Respiratory Solution 250mcg/ml	Ipratropium bromide 250mcg/ml - 15 ml	Oral	19791	823306
144	Ipravent/Levoline Nebulisation Solution	Ipravent/Levoline Nebulisation Solution	Oral	73688	224010
145	Iron And Folic Acid Paediatric Drop	Each ml to contain: Colloidal Iron Eqv. to Elemental Iron 25 mg, Lysine Hydrochloride 200 mg, Vit. B12- 5 mcg, Folic Acid 200 mcg	Oral	2250	46800
146	Isapaghul Powder Granules 90gm	Isapaghul Powder Granules Each 15gm contains Lactilol Monohydrate NF 10gm, Isapghula Husk IP 3.5gm, Excipients q.s., 90 gm Sachet	Oral	391311	28174392
147	Ispaghula Granules/Husk/Powder (Herbal medicine)	Ispaghula Granules/Husk/Powder (Herbal medicine)	Oral	217406	45916200
148	Laxative Powder	Each Sachet 137.15gm contains:Polyethylene Glycol IP 118gm Potassium Chloride IP 1.484gm Sodium Chloride IP 2.93gm Sodium Bicarbonate IP 3.37gm Sodium Sulphate 11.36gm	Oral	1125	146295
149	Magnesium Sulphate powder I.P. 400 gm packet	Magnesium Sulphate powder I.P. 400 gm packet	Oral	6482	217804

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
150	Magnesium Sulphate powder I.P. 500gm packet	Magnesium Sulphate powder I.P. 500gm packet	Oral	113571	3367153
151	Methadone Oral Solution 5mg/ml	Methadone Oral Solution 5mg/ml	Oral	1000	17600
152	Methylcellulose Powder 2gm	Methylcellulose Powder 2gm, 100 gm Packet	Oral	1000	26800
153	Metoclopramide Oral Liquid 5 mg/5 ml	Metoclopramide Oral Liquid 5 mg/5 ml	Oral	270891	439927
154	Midazolam nasal spray 0.5mg	Midazolam nasal spray 0.5mg 50 metered doses 5ml	Oral	54970	10422265
155	Moxifloxacin 0.5% with prednisolone 1% Eye Drop 5ml vial	Moxifloxacin Hydrochloride equivalent to Moxifloxacin 0.5% w/v, prednisolone acetate usp 1% w/v, Benzalkonium Chloride solution as preservative IP 0.02% w/v sterile aqueous base q.s. 5ml vial	Oral	7650	446760
156	N-acetylcysteine Sachet 200mg	N-acetylcysteine Sachet 200mg	Oral	1000	36000
157	Nitrofurantoin Oral liquid 25mg/5ml	Nitrofurantoin Oral liquid 25mg/5ml	Oral	271782	14502288
158	Nystatin	Nystatin Oral Liquid 1 Lac IU/ml	Oral	279801	6289926
159	Oral Rehydration Salt Powder as per WHO formula 20.5gm Sachet	Sachet Oral Rehydration Salt Powder as Per WHO Formulation -for the Diarrhoeal Diseases Control Programme,& of the United Nation Childrens Fund(UNICEF) As Per Amendment I P 2005 Composition g/l Sodium Chloride IP 2.60 g, Potassium Chloride IP 1.50 g, Sodium Citrate IP 2.90 g, Anhydrous Dextrose IP 13.50 g The Composition of the formulation described above in terms of amount in gm to be dissolved in sufficient water to produce 1000 ml.The total osmolar concentration of the solution in terms of mosmol per litre is 245	Oral	482091694	981731525
160	ORC Powder	Laprosopic applicator 2in 1 for application of oxidized Regenerated cellulose in Lap and Endoscopic procedure	Oral	1000	7120000
161	ORS + Pre & Probiotic Sachet	Each Pack-in-Pack Sachet WHO Oral Rehydration Salt Pack 4.10g contains: Sodium Chloride 0.52gm,Sodium Citrate 0.58gm,Potassium Chloride 0.3gm,Dextrose Anhydrous 2.7gm Pre & Probiotic Pack 0.5g contains: Streptococcus Faecalis T-110 7.5 Million,Clostridium Butyricum TO-A 0.5	Oral	87075	748204

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
		Million,Bacillus Mesentericus TO-A 0.25 Million,Lactobacillus Sporogenes 20.0 Million			
162	Para-Amino Salicylic acid (PAS)- 100 gm Granules	Para-amino salicylic acid (PAS)- Granules 100 gm	Oral	6109	4887
163	Phenytoin Oral Liquid 30mg/5ml, 125mg/5ml	Phenytoin Oral Liquid 30mg/5ml, 125mg/5ml	Oral	1782	35640
164	Potassium Chloride Oral Liquid 500 mg/5ml	Potassium Chloride Oral Liquid 500 mg/5ml	Oral	81270	1495368
165	Potassium Permanganate Crystals I.P. 450 gms Packet	Potassium Permanganate Crystals I.P. 450 gms Packet	Oral	1586	230704
166	Povidine- Iodine Germicide Garle 20% w/v	Povidone Iodine 20% w/v Gargle Solution IP	Oral	1230930	196948800
167	Povidone Iodine germicide Gargle 2% w/v	Povidone Iodine Germicide Gargle 2% w/v	Oral	23513	284407
168	Pre and Probiotic Sachet	Pre and Probiotic Granules Each Sachet (0.5g) contains: Streptococcus Faecalis T-110 JP 30 Million Clostridium Butyricum TO - A 2 Million Bacillus Mesentericus TO - A JPC 1 Million Lactic Acid Bacillus 50 Million (Lactobacillus Sporogenes)	Oral	20250	125556
169	Prednisolone Oral Liquid 15mg/5ml	Prednisolone Oral Liquid 15mg/5ml	Oral	1000	32000
170	Prednisolone Oral Liquid 5mg/5ml	Prednisolone Oral Liquid 5mg/5ml	Oral	54891	483041
171	Pyrazinamide Oral Liquid 250mg/5ml	Pyrazinamide Oral Liquid 250mg/5ml	Oral	1000	20800
172	Risperidone Oral Liquid 1 mg/ml	Risperidone Oral Liquid 1 mg/ml contains; Risperidone 1 mg/ml	Oral	1000	48000
173	SALBUTAMOL 100 mcg	SALBUTAMOL 100 mcg INHALER OF 200MDI	Oral	241731	32875416
174	Salbutamol Inhalation 100 mcg/dose	Salbutamol Inhalation 100 mcg/dose 200metered doses	Oral	1000	100480
175	Salbutamol Respirator Solution for use in Nebuliser 5mg/ml	Salbutamol respirator solution for use in nebuliser 5mg/ml	Oral	270891	1950415

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
176	Salbutamol Respules 2.5mg/2.5ml	Salbutamol Respirator Solution 2.5 mg/2.5 ml	Oral	46125	195939
177	Salmeterol Inhaled Bronchodilator	Salmeterol Inhaled Bronchodilator	Oral	1000	76800
178	Soda lime granules for Anesthesia I.P. 5Kg Jar	Soda lime granules for Anesthesia I.P. 5Kg Jar	Oral	1000	144000
179	Tiotropium Inhalation (DPI) 18 mcg/dose	Tiotropium Inhalation (DPI) 18 mcg/dose	Oral	1000	556000
180	Tiotropium Inhalation (MDI) 9 mcg/dose	Tiotropium Inhalation (MDI) 9 mcg/dose	Oral	1000	296000
181	Tooth Paste (Potassium Nitrate)	Tooth Paste (Potassium Nitrate)	Oral	2403	46138
182	Vitamin D3 granules 60,000 IU/gm Sachet	Vitamin D3 60,000 Granules in 1 gm Sachet	Oral	16641	43333
183	Xylometazoline Nasal Drop 0.05% 10 ml (Paediatric)	Each Spray Contains Xylometazoline HCl 0.05% in aqueous isotonic solution Purified water IP Benzalkonium Chloride 0.01% (10ml)	Oral	270891	4730840
184	Xylometazoline Nasal Drop 0.10% 10 ml (Adult)	Each Spray Contains Xylometazoline HCl 0.1% in aqueous isotonic solution Purified water IP Benzalkonium Chloride 0.02% (10ml)	Oral	707751	26084871
185	Zidovudine Oral Liquid 50mg/5ml	Zidovudine Oral Liquid 50mg/5ml	Oral	1000	41600
186	Zinc Oxide Eugenol	Zinc Oxide Eugenol	Oral	2403	288360

Appendix B: Checklist

(Mandatory Documents to be uploaded online in the EOI)

For the avoidance of any confusion, scanned copies of the above-mentioned documents shall be uploaded online on the Official Website on or prior to the EOI Due Date.

Sr. No.	DOCUMENTS.	Compliance	Page No. (as per the Bid)
1	Copy of certificate of incorporation/registration along with charter documents, and other registration documents according to the nature of entity	Yes / No	
2	Pan Card Details	Yes / No	
3	GST Registration certificate along with copy of the GST return of last quarter.	Yes / No	
4	Copy of manufacturing drug license with product list duly approved by the Licensing Authority/ State drug authority for each and every product quoted as per specification in the bid. The license must have been duly renewed up to date and the items quoted shall be clearly highlighted in the license	Yes / No	
5	World Health Organization-Good Manufacturing Practice certificate with either product list or COPP	Yes / No	
6	Copy of permission from DCGI for "New drug & Fixed Dose Combination"	Yes / No	
7	Market Standing Certificate as issued by Central or State Licensing Authority for relevant period against quoted Drugs	Yes / No	
8	Non-Conviction Certificate issued by Licensing Authority.	Yes / No	
9	Annexure-1 (Technical Specifications and Compliance)	Yes / No	
11	Annexure-2 (Undertaking by EOI Respondent)	Yes / No	
12	Annexure-3 (Proforma for Production and Sale Statement)	Yes / No	
13	Annexure-4 (Details of Manufacturing Unit)	Yes / No	
14	Annexure-5 (Details of Items Quoted with Drug Code)	Yes / No	
15	Annexure-6 (Annual Turnover Statement for Three Years) along with Copies of Balance Sheet and Profit and Loss Accounts for last three years i.e., (2023-24,	Yes / No	

Sr. No.	DOCUMENTS.	Compliance	Page No. (as per the Bid)
	2024-25 and 2025-26) certified by the Statutory Auditor or Chartered Accountant.		
16	Annexure-7 (Format for Power of Attorney for signing of EOI)	Yes / No	
17	Annexure-8 (Affidavit for Blacklisting)	Yes / No	
18	Annexure-9 (Litigation Affidavit)	Yes / No	
19	Annexure-10 (Mandate Form)	Yes / No	
20	Annexure -11 Delivery and Supply Capability	Yes / No	
21	Annexure-12 Respondent Classification	Yes / No	
22	Import Export Certificate (IEC Code) for Importer	Yes / No	
23	GST Registration certificate along with copy of the GST return of last quarter.	Yes / No	

Annexure 1: Technical Specifications and Compliance

Item Name: Following are the minimum requirements. Products offered must meet these parameters herein.

Sr. No	Item Name	Technical specification s/ composition of tender enquiry	Compliance on each parameter with detailed substantiation how the offered product meets the requirement.	If Column B=C (write Yes or No)	Generic Name / Brand Name (only for Importer)	Drug Mfg. License (Form 25 or 28 & 26)/ Medical devices/ Import License (Form 10 & 41)	MSM E/ SSI	Remarks, if any
	A	B	C	D	E	F	G	H

Note:

- Pharmacopoeia standards IP/BP/USP etc. should be clearly mentioned against each drug/constituent of the formulation quoted as per the provisions of the Applicable Laws.
- Active ingredient used in formulation of item quoted shall be of mentioned Pharmacopoeia quality & Specifications.

Sign

Stamp

Date

Annexure-2: Undertaking by EOI Respondent

To,
Chief Executive Officer,
Maharashtra Medical Goods Procurement Authority,
1st Floor, Aarogya Bhawan,
Near CSMT Railway Station, Mumbai 400001 (Maharashtra)

Subject: EOI for the [*****]

Dear Sir,

With reference to your EOI dated _____, I, having examined the document and understood its contents, hereby submit my/our EOI for the aforesaid [*****]. The EOI is submitted voluntarily and without reservation, solely for market assessment purposes.

1. I/ We acknowledge that MMGPA will be relying on the information provided in the EOI and the documents accompanying such EOI, and we certify that all information provided therein is true and correct; nothing has been omitted which renders such information misleading; and all documents accompanying such EOI are true copies of their respective originals.
2. I/ We shall make available to MMGPA any additional information it may find necessary or require supplementing or authenticate the EOI.
3. I/ We declare that:
 - a) I/ We have examined and have no reservations to the EOI, including any Addendum / Corrigendum issued by MMGPA.
 - b) I/ We do not have any conflict of interest in accordance with the EOIs; and
 - c) I/We have not directly or indirectly or through an agent engaged or indulged in any unethical practice, as defined in the EOI, in respect of any tender or request for proposal issued by or any agreement entered into with MMGPA or any other public sector enterprise or any government, Central or State.
4. I/ We understand that this EOI is purely for market analysis purpose and you may not issue any following tender or empanelment process after this.
5. I/ We certify that we the Annual Turnover and Net Worth given by us is correct to the best of our knowledge.
6. I/ We certify that in regard to matters other than security and integrity of the country, we or any of our associates have not been convicted by a Court of Law or indicted or adverse orders passed by a regulatory authority which could cast a doubt on our ability to undertake the Contract or which relates to a grave offence that outrages the moral sense of the community.
7. I/ We further certify that in regard to matters relating to security and integrity of the country, we or any of our associates have not been charge-sheeted by any agency of the Government or convicted by a Court of Law.
8. I/ We further certify that no investigation which materially affects regulatory compliance or manufacturing/import operations is pending either against us or against our associates or against our CEO or any of our directors/ managers/ employees / Partners /Trustees.
9. I/We further certify that we or any of our Associates are not barred by the Central Government/ State Government or any entity controlled by it, from participating in any supply of drugs contract, and no bar subsists as on the EOI Due Date.

10. The power of attorney for signing of EOI, as per format provided at Annexure-6 of the EOI, is also enclosed.

In witness thereof, I/we submit this EOI under and in accordance with the terms of the EOI.

Yours faithfully,

Date:

(Signature, Name and designation of the Authorised signatory)

Place:

(Name and seal of Responder)

Annexure-3: Proforma for Production and Sale Statement

Name of the EOI Respondent entity:

Sr. No.	Year	Name and full Address of the Purchaser	Purchasing Entity (Gov./Semi Gov./Reg. under Trust)	Name of the Product	Purchase Order No. & Date	Purchase Order Quantity	Batch No.		PO Copy enclosed on Pg. No.
							Manufactured Qty	Sold Qty	
1	2023-24								
2	2024-25								
3	2025-26								

Add rows as per requirement.

Note:

1. In support of above statement, enclose the copies of supply orders and client's satisfactory certificates. All purchase orders should be enclosed in the serial as per the data provided in table above.
2. In case of importer, sold quantity shall be provided, production and manufactured good details may not be provided-
3. All the data of the bidding entity, as provided in the above table has been verified by undersigned Chartered Accountant/Statutory Auditor.
4. The issuer of this certificate must ensure that the above information/details are related to the bidding entity only.

Name, Membership number and signature of the Chartered Accountant/Statutory Auditor: UDIN

Name and seal of the firm:

Location, Date:

Authorized Signature (PoA holder)

[In full and initials with Seal]:

Name and Title of Signatory:

Name of Bidder (Firm/ Organization's name): Address:

Telephone:

Email:

(Name and seal of the Bidder)

[Location, Date]

Annexure 4: Details of Manufacturing Unit

(The details of manufacturing facility to be furnished)

- 1 Name of the EOI Respondent :
- 2 Registered Office Address :
- 3 Manufacturing Unit Address :
- 4 PAN :
- 5 GST No. :
- 6 Manufacturing License No.:
- 7 Date of Issue :
- 8 Valid up to / Retention :
- 9 Issued by (SLA / CLA) :
- 10 WHO-GMP / Equivalent Certification:
 - a. Certifying Authority
 - b. Certificate Validity
- 11 Details of Installed Manufacturing Capability (Indicative)

Type	Indicative Capability Details
Tablets	
Capsules	
Injections	
IV Fluids	
Sterile Powders	
Liquids / Syrups	
Ointments / Creams	
Other (specify)	

Declaration

I/We hereby declare that the information furnished above is true and correct to the best of my/our knowledge and belief.

Signature of Authorized Signatory :

Name :

Designation :

Date :

Place :

Details of Installed Production Capacity for 30 days
(In Terms of Unit Packs)

Tablets :

Capsules:

General:

Beta-Lactum :

Injection

Ampoules :

Vials :

I.V.Fluids :

Sterile Powder:

Liquids

Suspension :

Syrups :

Drops :

Ointment :

Powders :

Antiseptics/

Disinfectants :

Name & designation of the authorized signatory:

Specimen signature of the authorized Signatory:

*The details of manufacturing unit should be for the premises where drugs quoted are actually manufactured.

THE DETAILS OF FACTORY PREMISES

Person In-charge of Factory

Name :

Phone No. :

Mobile No. :

Nearest Landmark of Factory:

Layout

Km from Airport :

Name of the Airport and City:

Km from Railway Station :

Name of the Railway Station :

Km from Bus Stand :

Name of the Bus Stand :
And City

All the data provided in the above table has been verified by undersigned Chartered Accountant/Statutory Auditor.

Name, Membership number and signature of the Chartered Accountant/Statutory Auditor: UDIN

Name and seal of the firm:

Location, Date:

Authorized Signature (PoA holder)

[In full and initials with Seal]:

Name and Title of Signatory:

Name of Bidder (Firm/ Organization's name): Address:

Telephone:

Email:

(Name and seal of the Bidder)

[Location, Date]

Annexure-4 (A): Proof of Distribution Network

A. Distribution / Logistical Details

S.No	Particulars	Details
1	Whether distribution/logistics arrangement exists	Yes / No
2	Nature of arrangement (Own / Third-party / Proposed)	
3	Broad geographic coverage	
4	Presence in Maharashtra (if any)	Yes / No
5	Any other relevant details	

B. Authorised Distributors / Logistic Partners (If Applicable)

Sr. No.	Name	Address
1		
2		

Declaration

I/We hereby declare that the information furnished above is true and correct to the best of my/our knowledge and belief.

Signature of Authorized Signatory :

Name :

Designation :

Date :

Place :

Annexure-5: Details of Items Quoted with Drug Code

1. Name of the firm:
2. Address as given in drug licence:
3. Drug Licence No. in Form 25 &28:
4. Import Licence No. :
5. Date of issue:
6. Validity:
7. Non-conviction Certificate obtained on:
8. Market standing certificate obtained on:
9. Details of endorsement for all products:

Sr. No.	Drug name	Specifications IP/BP/USP	Date of endorsement obtained from State Drugs Commissioner	Whether Endorsement is in Generic or Brand Name

Add As Many Rows as possible You Want to Add

(Additional column should be inserted asking date of permission from CDSCO, in case of all newly introduced drugs and Fixed dose combinations)

Annexure 6: Annual Turnover Statement for Three Years

M/s. is participating in Tender No..... Items details as per Below Table.

Sr. No. of Item (as per Appendix A)	Name of Item	Required Turnover (In Rs)
Total Required Turnover		

The Average Annual Turnover and Net Worth details of M/s _____ for participation under the Tender Document are given below and certified that the statement is true and correct.

Sr. No.	Year	Turnover (In Rs.)
1		
2		
3		
4		
Net Worth		
5	Net worth in the latest financial year preceding the Bid Due Date (positive/negative)	

“Net Worth” in case of Company shall mean the aggregate value of the paid-up share capital and all reserves created out of the profits and securities premium account, after deducting the aggregate value of the accumulated losses, deferred expenditure and miscellaneous expenditure not written off, as per the audited balance sheet, but does not include reserves created out of revaluation of assets, write-back of depreciation and amalgamation.

For other eligible entities, the Net Worth shall mean the amount derived by subtracting the liabilities from the assets as certified by the chartered accountant/statutory auditor having valid registration.

Note:

1. Certificate issued by a statutory auditor/chartered accountant along with audited financial statements confirming the average annual turnover of the Bidder during the stated financial years must be submitted on the letterhead of the statutory auditor/chartered accountant.
2. Provide supporting audited financial statements (Balance Sheets, Profit and Loss Statements, etc.) of the bidding entity.
3. The Net Worth of the bidder in the financial year immediately preceding the Bid Due Date should be positive.
4. “Turnover” for the purposes of this Tender Document shall mean the monetary value of goods sold by the Bidder.

Name, Membership number and signature of the Chartered Accountant:

UDIN

Name and seal of the firm:

Location, Date:

Authorized Signature of Bidder (PoA holder)

[In full and initials with Seal]:

Name and Title of Signatory:

Name of Bidder (Firm/ Organization's name):

Address:

Telephone:

Email:

(Name and seal of the Bidder)

[Location, Date]

Annexure-7: Format for Power of Attorney for signing of EOI

(To be executed as an Affidavit on a Stamp paper of appropriate value)

Know all men by these presents, We, (name of the firm and address of the registered office) do hereby irrevocably constitute, nominate, appoint and authorize Mr. / Ms (Name), son/daughter/wife of..... and presently residing at, who is presently employed with us and holding the position of, as our true and lawful attorney (hereinafter referred to as the “**Attorney**”) to do in our name and on our behalf, all such acts, deeds and things as are necessary or required in connection with or incidental to submission of our EOI for the [*****], proposed or being developed by the [*****] (the “**Purchaser**”) including but not limited to signing and submission of all applications, EOIs and other documents and writings, participate in Responders' and other conferences and providing information / responses to MMGPA, representing us in all matters before MMGPA, signing and execution of all contracts including the Contract and undertakings consequent to acceptance of our EOI, and generally dealing with MMGPA in all matters in connection with or relating to or arising out of our EOI for the said Contract and/or upon award thereof to us and/or till the entering into of the Contract with MMGPA.

AND we hereby agree to ratify and confirm and do hereby ratify and confirm all acts, deeds and things done or caused to be done by our said Attorney pursuant to and in exercise of the powers conferred by this Power of Attorney and that all acts, deeds and things done by our said Attorney in exercise of the powers hereby conferred shall and shall always be deemed to have been done by us.

IN WITNESS WHEREOF WE, ..., THE
ABOVE-NAMED PRINCIPAL HAVE EXECUTED THIS POWER OF ATTORNEY ON
THIS
DAY OF, 20.....

For

(Signature, name, designation and address of person authorized by Board Resolution
in case of Firms/Company)/Partner in case of
Partnership Firms

Witnesses:

1.

2.

Notarised Person identified by me/personally appeared before me

/Signed before me/Attested/Authenticated* (*Notary to specify as applicable) (Signature, Name and Address of the Notary)

Seal of the Notary Registration Number of the Notary

Date____

Signature, name, designation and address of the Attorney)

Notes:

- The mode of execution of the Power of Attorney should be in accordance with the procedure, if any, laid down by the applicable law and the charter documents of the executants (s) and when it is so required, the same should be under common seal affixed in accordance with the required procedure.

Wherever required, the Responder should submit for verification the extract of the charter documents and documents such as a board or shareholders resolution/power of attorney in favour of the person executing this Power of Attorney for the delegation of power hereunder on behalf of the Responder.

- For a Power of Attorney executed and issued overseas, the document will also have to be legalized by the Indian Embassy and notarized in the jurisdiction where the Power of Attorney is being issued. However, the Power of Attorney provided by Responders from countries that have signed the Hague Legislation Convention, 1961 are not required to be legalized by the Indian Embassy if it carries a conforming Apostille certificate issued by the designated competent authority and has been notarized by the public notary.

Annexure-8: Undertaking for Non-blacklisting

(on Letterhead of the Respondent)

EOI reference No:E-291/MMGPA/ EOI for Liquid Orals (2026-27)

1. I/We, (Name of the Responder), the Responder herein, has not been found guilty of malpractices, misconduct or Blacklisted/Debarred/ deregistered for the quoted product by any department of Govt. of Maharashtra or by any local authority and semi Govt. organization and other State Government/Central Government's organizations/ procurement corporation as on the date of submission EOI for the quoted items.

4. I/We undertake that I/we are not involved in any major litigation such as fraud, FEMA violations and any other civil or criminal proceedings.

Seal

Signature of Authorized Signatory

Date

Place

Verification

I, the above named [*Name of the Responder*], do hereby solemnly verify that the contents of the above Affidavit are true and correct to my knowledge and belief. Nothing false has been stated therein or material concealed therefrom.

Verified at {*location*} on {*Date*}

Annexure- 9: Litigation Affidavit

(on Non-judicial Stamp Paper of Rs.500/-)

EOI reference No:E-291/MMGPA/ EOI for Liquid Orals (2026-27)

I _____ age _____ address(authorized signatory to sign the contract), hereby submit, vide this affidavit in truth, that I am the owner/authorized signatory of the bidding entity and I am submitting the documents in Envelope no.1 for the purpose of security of the contract. I hereby agree to the conditions mentioned below:-

1. I am liable for action under Bharatiya Nyaya Sanhita (BNS) for submission of any false/ fraudulent paper/information submitted in Envelope no.1
2. I am liable for action under Bharatiya Nyaya Sanhita (BNS) if during contract period and any false information, false bill of purchases supporting proof of purchase, proof of testing submitted by my staff, subletting company or by myself, I will be liable for action under Bharatiya Nyaya Sanhita (BNS).
3. I am liable for action under Bharatiya Nyaya Sanhita (BNS) if any paper is found false / fraudulent during contract period and even after the completion of contract (finalization of final bill).

Authorised Signature of Bidder

Seal of Company

Verification

I, the above named [*Name of the Bidder*], do hereby solemnly verify that the contents of the above Affidavit are true and correct to my knowledge and belief. Nothing false has been stated therein or material concealed therefrom.

Verified at {*location*} on {*Date*}

Annexure-10: Litigation Affidavit

01	Company Name	
02	Postal Address of the company with Telephone No., Fax No. and Mail address	
03	Name of the Managing Director/ Director/Manager Mobile No. /Phone No. E-mail address	
04	Name and designation of the authorized company official Mobile No. /Phone No. E-mail address	

Bank Details

01	Name of the Bank Branch Name & Address: Branch Code No. Branch Manager Mobile No. Branch Telephone no. Branch E-mail ID	
02	9-digit MICR code number of the bank and branch appearing on the MICR cheque issued by the bank.	
03	IFSC code of the Branch	
04	Type of Account (Current/Savings)	
05	Account Number (as appear in cheque book)	

(in lieu of the bank certificate to be obtained, please **attach the original cancelled cheque** issued by your bank for verification of the above particulars)

I/We hereby declare that the particulars given above are correct and complete. If the transaction is delayed or not effected at all for reasons of incomplete or incorrect information, I would not hold Maharashtra Medical Goods Procurement Authority, Mumbai. I have read the conditions of tender/ agreement entered and agree to discharge the responsibility expected of me/from the company as a tenderer/ successful bidder.

Date

Company Seal

Signature

Place

(Name of the person signing & designation)

CERTIFIED THAT THE PARTICULARS FURNISHED ABOVE BY THE COMPANY ARE CORRECT AS PER OUR RECORDS.

Bank Seal with address

Signature of the Authorized Official of the bank

Annexure 11: Delivery and Supply Capability

(To be submitted on the letterhead of the EOI Respondent)

This Annexure is intended to capture indicative information on the delivery readiness and supply capability of the EOI Respondent for the purpose of market assessment.

A. General Information

Name of the EOI Respondent: _____

Type (OEM / Authorized Importer): _____

Sr. No.	Parameter	Details
1	Average Production Lead Time (in days)	
2	Average Dispatch Time after production readiness (in days)	
3	Expected Delivery Timeline to Maharashtra (in days)	
4	Emergency Supply Capability (Yes/No, give details)	
7	Warehousing Facility in Maharashtra (Yes/No, location)	
8	Cold Chain Facility (if applicable)	
9	Logistics Arrangement (Own / Third-party / Hybrid)	
10	Any other relevant information	

Note: Submission of a physical Delivery Challan at the time of delivery is mandatory. The challan must bear the signature and seal of the authorized accepting authority; without such acknowledgment, the delivery shall not be treated as complete.

Declaration

I/We hereby declare that the information furnished above is true and correct to the best of my/our knowledge and belief.

Authorized Signatory

Name: _____

Designation: _____

Date: _____

Place: _____

Annexure 11 (a) : Delivery Acceptance Certificate

FINAL ACCEPTANCE CERTIFICATE

Date: / /2026.

To,
Chief Executive Officer,
Maharashtra Medical Goods Procurement Authority,
1st Floor, Aarogya Bhawan,
St. George's Hospital Compound, Mumbai 400001
Maha.mmgsa2023@gmail.com

Subject: Acceptance Certificate for the supply of

Reference: Purchase Order No.

As per above mentioned reference purchase order, the said material has been received by this office / hospital in good condition & as per terms & condition of the purchase order. The details of the same are as follows;

Sr. No.	Particular(s)	Specific information
1	Name of Material Received	
2	Quantity as per Purchase Order	
3	Invoice Number with Date	
4	Batch Number(s) with Quantity	
5	Total Quantity Received	
6	Date of Receipt of Material	
7	Entry Taken in Stock Book	
8	Stock Book No.	
9	Page Number	
10	Name of the Supplier	
11	Name of the Manufacturer	
12	Address of the Manufacturer as per Invoice	
13	Material Received as per Technical Specifications mentioned in Purchase Order (YES/NO)?	

**This is certifying that, the above information is true on the basis of office record.

Name of Pharmacist/ Store In-charge;

Name of Office/ Hospital In-charge;

(Signature with Stamp)

(Signature with Stamp)

Date:

Place:

Mail id for Acceptance: maha.mmgsa2023@gmail.com

58 | Page

EOI for Liquid Orals

Annexure 12: Respondent Classification Details

(To be submitted on the letterhead of the EOI Respondent)

This Annexure captures classification details for MSME status, social category, and geographical presence.

A. Basic Details

Sr. No.	Parameter	Details
1	Name of EOI Respondent	
2	Type of Entity (Company / LLP)	
3	Nature (OEM / Authorized Importer)	

B. Classification Details

Sr. No.	Parameter	Details
1	MSME Status (Yes/No)	
2	MSME Registration Number	
3	SC/ST Ownership (Yes/No)	
4	Certificate Details	

C. Classification

Sr. No.	Classification Parameter	Select One
1	Location Classification	☐ Within Maharashtra ☐ Outside Maharashtra
2	MSME Category	☐ MSME (Within Maharashtra) ☐ MSME (Outside Maharashtra) ☐ Non-MSME
3	SC/ST Category	☐ SC/ST (Within Maharashtra) ☐ SC/ST (Outside Maharashtra) ☐ Not Applicable

Declaration

I/We hereby declare that the information furnished above is true and correct to the best of my/our knowledge and belief.

Authorized Signatory

Name: _____

Designation: _____

Date: _____

Place: _____